Yarrow Bioscience Announces $161.8M Public Offering

What Happened

• Yarrow Bioscience, Inc. announced on Sept. 10, 2026 that it entered an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC to sell common stock in a public offering.
• The offering was for 5,769,231 shares at $26.00 per share, and the underwriters had a 30-day option for an additional 865,384 shares which they exercised in full on Sept. 11, 2026, bringing the total to 6,634,615 shares.
• Net proceeds from the Offering, including the exercised option, are expected to be approximately $161.8 million after underwriting discounts, commissions and estimated expenses. The offering is tied to the Company’s Form S-3 shelf registration (declared effective Aug. 19, 2026) and was expected to close on Sept. 14, 2026.

Key Details

• Shares offered: 5,769,231 initially; Option exercised: 865,384 additional shares; Total: 6,634,615 shares.
• Public offering price: $26.00 per share.
• Expected net proceeds: ≈ $161.8 million (after fees and expenses).
• Underwriters / reps: Jefferies LLC, TD Securities (USA) LLC, Guggenheim Securities, LLC.
• Lock-up: Directors and executive officers agreed not to sell shares for 60 days after the final prospectus supplement (with limited exceptions).
• Regulatory filings: Offering made under the Company’s Form S-3 shelf registration; final prospectus supplement dated Sept. 10, 2026 filed Sept. 11, 2026.

Why It Matters

• The offering will provide Yarrow with a substantial cash infusion (about $161.8M net), which can support operations, R&D, clinical programs, or other corporate needs.
• It creates dilution for existing shareholders because new shares are being issued at $26.00 per share. Investors should weigh the expected use of proceeds against the dilution impact.
• The 60-day lock-up restricts insider sales in the short term, which can limit near-term insider-driven selling pressure but does not prevent future dilution from additional financings.